Evidence map›Paper›PMID 25002580›Full record

ArticleThe Journal of biological chemistry2014

Deciphering a molecular mechanism of neonatal diabetes mellitus by the chemical synthesis of a protein diastereomer, [D-AlaB8]human proinsulin.

Michal Avital-Shmilovici, Jonathan Whittaker, Michael A Weiss, Stephen B H Kent

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Distinct states of proinsulin misfolding in MIDY.Cellular and molecular life sciences : CMLS · 2021
    Article
  8. Review
  9. Article
  10. Evolution of insulin at the edge of foldability and its medical implications.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Michal Avital-ShmiloviciFrom the Departments of Chemistry, and Biochemistry and Molecular Biology, Institute for Biophysical Dynamics, University of Chicago, Chicago, Illinois 60637 and.
Jonathan Whittakerthe Departments of Biochemistry and.
Michael A Weissthe Departments of Biochemistry and Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio 44106.
Stephen B H KentFrom the Departments of Chemistry, and Biochemistry and Molecular Biology, Institute for Biophysical Dynamics, University of Chicago, Chicago, Illinois 60637 and skent@uchicago.edu.
Case Western Reserve University · USUniversity of Chicago · US

Funding

Non-Standard Protein Design in Molecular Endocrinology: Insulin and GlucagonR01DK040949 · NIDDK · UNIVERSITY OF CHICAGO · PI CHERRINGTON, ALAN D, GEORGIADIS, MILLIE M · 1989 to 2024
$8.4M
How mutations in proinsulin cause diabetes: a protein-misfolding diseaseR01DK069764 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI ARVAN, PETER, KENT, STEPHEN B.H. · 2004 to 2014
$3.5M
NIDDK NIH HHS R01 DK040949NIDDK NIH HHS R01 DK069764
6 · The paper itself

Abstract

Misfolding of proinsulin variants in the pancreatic β-cell, a monogenic cause of permanent neonatal-onset diabetes mellitus, provides a model for a disease of protein toxicity. A hot spot for such clinical mutations is found at position B8, conserved as glycine within the vertebrate insulin superfamily. We set out to investigate the molecular basis of the aberrant properties of a proinsulin clinical mutant in which residue Gly(B8) is replaced by Ser(B8). Modular total chemical synthesis was used to prepare the wild-type [Gly(B8)]proinsulin molecule and three analogs: [D-Ala(B8)]proinsulin, [L-Ala(B8)]proinsulin, and the clinical mutant [L-Ser(B8)]proinsulin. The protein diastereomer [D-Ala(B8)]proinsulin produced higher folding yields at all pH values compared with the wild-type proinsulin and the other two analogs, but showed only very weak binding to the insulin receptor. The clinical mutant [L-Ser(B8)]proinsulin impaired folding at pH 7.5 even in the presence of protein-disulfide isomerase. Surprisingly, although [L-Ser(B8)]proinsulin did not fold well under the physiological conditions investigated, once folded the [L-Ser(B8)]proinsulin protein molecule bound to the insulin receptor more effectively than wild-type proinsulin. Such paradoxical gain of function (not pertinent in vivo due to impaired secretion of the mutant insulin) presumably reflects induced fit in the native mechanism of hormone-receptor engagement. This work provides insight into the molecular mechanism of a clinical mutation in the insulin gene associated with diabetes mellitus. These results dramatically illustrate the power of total protein synthesis, as enabled by modern chemical ligation methods, for the investigation of protein folding and misfolding.

Indexed as

AlanineChromatography, High Pressure LiquidChromatography, Reverse-PhaseDiabetes MellitusHumansInfant, NewbornInfant, Newborn, DiseasesProinsulinSpectrometry, Mass, Electrospray IonizationStereoisomerismAlanineProinsulinChemical BiologyDiabetesInsulin ReceptorMutantPeptide Chemical SynthesisProinsulinProtein Folding

Identifiers

PMID25002580
PMCPMC4156091
OpenAlexW1982168813

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.